Telix Q2 Revenue Reaches $247M, FY2026 Guidance Lifted Above $1B
TLX sits 68% above its 52-week low of $6.28.
Summary
Telix posted Q2 2026 revenue of $247 million, a 21% year-over-year increase, and raised full-year guidance to over $1 billion. The update also highlighted progress across multiple late-stage pipeline programs, including FDA alignment on a pivotal prostate cancer trial and a September PDUFA date for its brain imaging agent.
Key Events · Earnings and Guidance · TLX
-
Q2 Revenue Beats, Guidance Raised
Revenue reached $247M in Q2 2026, a 21% year-over-year increase, with Precision Medicine up 30%. FY2026 revenue guidance was raised to over $1B, including $40M from Regeneron.
-
FDA Greenlights Pivotal Prostate Cancer Trial
The FDA confirmed that safety data from Part 1 of the ProstACT Global Phase 3 trial for TLX591-Tx are sufficient to proceed to Part 2 in the U.S., pending IND amendment review.
-
Brain Imaging NDA Accepted, PDUFA Set
The resubmitted NDA for Pixclara (TLX101-Px) was accepted by the FDA, with a PDUFA goal date of September 11, 2026. The European MAA was also validated.
-
Pipeline Advances Across Multiple Programs
The first patient was dosed in the LUTEON pivotal trial for kidney cancer; the IPAX BrIGHT pivotal trial for glioblastoma enrolled its first cohort; and the Japan Phase 3 study for Illuccix completed enrollment.
Analysis · TLX · Life Sciences
A 21% year-over-year revenue surge, fueled by the Precision Medicine segment, powered a standout quarter for Telix. The full-year outlook now exceeds $1 billion, incorporating a $40 million upfront payment from Regeneron alongside robust commercial momentum. Late-stage pipeline de-risking is evident across multiple fronts: FDA alignment on a pivotal prostate cancer trial, completed enrollment in a Japanese Phase 3 study, and acceptance of a brain imaging NDA with a September PDUFA date. Raising R&D spend to as much as $270 million underscores confidence in accelerating high-value programs, though it may weigh on near-term profitability. For a $3.5 billion biotech, crossing the $1 billion revenue threshold signals a transition to commercial scale, with the pipeline offering multiple shots on goal for further upside.
At the time of this filing, TLX was trading at $10.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $6.28 to $16.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.